Document is current
Any future updates will be listed below
-
Authors
Haffer, Henryk
Muellner, Maximilian
Chiapparelli, Erika
Dodo, Yusuke
Camino-Willhuber, Gaston
Zhu, Jiaqi
Tan, Ek T.
Pumberger, Matthias
Shue, Jennifer
Sama, Andrew A.
Cammisa, Frank P.
Girardi, Federico P.
Hughes, Alexander P. https://orcid.org/0000-0001-7293-9672
-
Funding
Funding for this research was provided by:
National Center For Advancing Translational Science of the National Institute of Health (UL1TR00238)
- License Information
-
More Information
Article History
Received: 7 April 2024
Revised: 7 April 2024
Accepted: 9 April 2024
First Online: 27 May 2024
Declarations
:
: The Authors declare that there is no conflict of interest concerning materials or methods used in this study or the findings specified in this paper.
: Dr. Sama reports royalties from Ortho Development, Corp.; private investments for Vestia Ventures MiRUS Investment, LLC, ISPH II, LLC, ISPH 3, LLC, and VBros Venture Partners X Centinel Spine; consulting fee from Clariance, Inc., Kuros Biosciences AG, and Medical Device Business Service, Inc.; speaking and teaching arrangements of DePuy Synthes Products, Inc.; membership of scientific advisory board of Clariance, Inc., and Kuros Biosciences AG; and trips/travel of Medical Device Business research support from Spinal Kinetics, Inc., outside the submitted work. Dr. Cammisa reports royalties from NuVasive, Inc.; private investments for 4WEB Medical/4WEB, Inc., Bonovo Orthopedics, Inc., Healthpoint Capital Partners, LP, ISPH II, LLC, ISPH 3 Holdings, LLC, Ivy Healthcare Capital Partners, LLC, Medical Device Partners II, LLC, Medical Device Partners III, LLC, Orthobond Corporation, Spine Biopharma, LLC, Synexis, LLC, Tissue Differentiation Intelligence, LLC, VBVP VI, LLC, VBVP X, LLC (Centinel) and Woven Orthopedics Technologies; consulting fees from 4WEB Medical/4WEB, Inc., DePuy Synthes Spine, NuVasive, Inc., Spine Biopharma, LLC, and Synexis, LLC; membership of scientific advisory board/other office of Healthpoint Capital Partners, LP, Medical Device Partners III, LLC, Orthobond Corporation, Spine Biopharma, LLC, Synexis, LLC, and Woven Orthopedic Technologies; and research support from 4WEB Medical/4WEB, Inc., Mallinckrodt Pharmaceuticals, Camber Spine, and Centinel Spine, outside the submitted work. Dr. Girardi reports royalties from Lanx, Inc., and Ortho Development Corp.; private investments for Centinel Spine, and BCMID; stock ownership of Healthpoint Capital Partners, LP; and consulting fees from NuVasive, Inc., and DePuy Synthes Spine, outside the submitted work. Dr. Hughes reports research support from NuVasive, Inc. and Kuros Biosciences AG; and fellowship support from NuVasive, Inc. and Kuros Biosciences AG, outside the submitted work.
: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
